# Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

> **NCT04686383** · PHASE1 · COMPLETED · sponsor: **Calgent Biotechnology Co., Ltd** · enrollment: 17 (actual)

## Conditions studied

- Resistant or Refractory Solid Tumors

## Interventions

- **DRUG:** CAL056 mesylate

## Key facts

- **NCT ID:** NCT04686383
- **Lead sponsor:** Calgent Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-29
- **Primary completion:** 2022-06-07
- **Final completion:** 2022-06-30
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04686383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04686383, "Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04686383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*